| March 1, 2028 |
IOVA |
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. |
Trial Milestone |
Phase 3 |
| March 1, 2028 |
CNSY |
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment |
Trial Milestone |
Phase 1 |
| March 3, 2028 |
ALZN |
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia |
Trial Milestone |
Phase 1/Phase 2 |
| March 7, 2028 |
NVS |
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab |
Trial Milestone |
Phase 1/Phase 2 |
| March 7, 2028 |
AMGN |
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone |
Trial Milestone |
Phase 4 |
| March 7, 2028 |
ARGX |
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod |
Trial Milestone |
Phase 2 |
| March 13, 2028 |
SNY |
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China |
Trial Milestone |
Phase 3 |
| March 14, 2028 |
INCY |
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms |
Trial Milestone |
Phase 1 |
| March 15, 2028 |
LLY |
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
LLY |
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) |
Trial Milestone |
Phase 1 |
| March 15, 2028 |
LLY |
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
ABBV |
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
ABBV |
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities |
Trial Milestone |
Phase 2 |
| March 15, 2028 |
ABBV |
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
GILD |
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| March 15, 2028 |
BNTX |
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| March 15, 2028 |
BNTX |
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
VNDA |
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
AXSM |
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
KLRA |
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
IMCR |
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
BCYC |
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) |
Trial Milestone |
Phase 2 |
| March 15, 2028 |
TARA |
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support |
Trial Milestone |
Phase 2/Phase 3 |
| March 15, 2028 |
GKOS |
Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant |
Trial Milestone |
Phase 2 |
| March 15, 2028 |
AVBP |
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| March 15, 2028 |
ABVX |
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis |
Trial Milestone |
Phase 2 |
| March 15, 2028 |
ORIC |
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
BCAX |
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC |
Trial Milestone |
Phase 2 |
| March 15, 2028 |
HALO |
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
ETRA |
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH) |
Trial Milestone |
Phase 2/Phase 3 |
| March 15, 2028 |
CNSY |
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma |
Trial Milestone |
Phase 1 |
| March 15, 2028 |
CGEM |
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease |
Trial Milestone |
Phase 1 |
| March 15, 2028 |
GNPX |
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib |
Trial Milestone |
Phase 1/Phase 2 |
| March 16, 2028 |
TAK |
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia |
Trial Milestone |
Phase 3 |
| March 16, 2028 |
NBIX |
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH) |
Trial Milestone |
Phase 2 |
| March 17, 2028 |
SVA |
Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old |
Trial Milestone |
Phase 4 |
| March 18, 2028 |
AMGN |
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) |
Trial Milestone |
Phase 1 |
| March 21, 2028 |
PFE |
Crizotinib Continuation Clinical Study |
Trial Milestone |
Phase 4 |
| March 21, 2028 |
SLDB |
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia |
Trial Milestone |
Phase 1 |
| March 25, 2028 |
REGN |
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments |
Trial Milestone |
Phase 1 |
| March 25, 2028 |
INCY |
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa |
Trial Milestone |
Phase 2 |
| March 27, 2028 |
KLRA |
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes |
Trial Milestone |
Phase 3 |
| March 30, 2028 |
JNJ |
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| March 31, 2028 |
TAK |
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India |
Trial Milestone |
Phase 4 |
| March 31, 2028 |
ALNY |
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy |
Trial Milestone |
Phase 3 |
| March 31, 2028 |
ADRX |
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients |
Trial Milestone |
Phase 1/Phase 2 |
| March 31, 2028 |
KYNB |
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Trial Milestone |
Phase 2 |
| March 31, 2028 |
PBYI |
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) |
Trial Milestone |
Phase 2 |